Uniseed

Uniseed is Australia’s longest-running venture fund, with investment capital provided by partner research organisations and a leading Australian Superannuation Fund, UniSuper.   These research organisations collectively spend over $7 billion on research annually, making up over 60% of the total research spend in all research organisations in Australia.

In November 2015, Uniseed started its third and largest fund (Fund-3), with the five initial partners, the Universities of Melbourne, Queensland, Sydney & New South Wales, and the CSIRO, each committing $10 million over 10 years (total fund $50 million).  This followed three high-profile exits in the preceding 14 months (Fibrotech sale to Shire; Spinifex sale to Novartis & Hatchtech sale to Dr Reddys Laboratories).

In March 2017, Uniseed announced the further commitment to a $20 million Follow-on Fund.

In January 2018, a Co-Investment Fund was established with private capital providers through a relationship with Stoic Venture Capital.

In March 2022, Uniseed announced strategic partnership and a further commitment of $75 million from leading Australian superannuation fund UniSuper.

In November 2023, five new partners joined the Uniseed partnership: Monash University, Macquarie University, the University of Technology Sydney, Western Sydney University and the University of Newcastle.